

## CHAPTER 3

---

# Transcriptional Regulation at the Neural Plate Border

Thomas D. Sargent\*

### Introduction

The neural crest (NC) is usually defined as a cell type arising at the border of the neural plate and the epidermis in vertebrate embryos. While accurate, this definition implies that the border exists as a distinct boundary, which is not really the case. Like other domains in the early embryo, the NC is not a sharply delimited territory, but rather is an overlapping zone of specification that has characteristics of both epidermis and neural plate, with additional characteristics of its own. This can be seen in the spatial pattern of regulatory factors that have been implicated in NC induction, many of which are shared.<sup>1</sup> For example *Msx1* and *AP2* are also expressed in the epidermis, at lower levels, and *c-myc* is likewise transcribed in neural plate in addition to NC. Nor is this limited to regulatory factors. The epidermal keratins, which constitute the intermediate filament cytoskeleton of epidermal cells are also expressed in NC, at a lower level than the epidermis. This can be seen by *in situ* hybridization (Fig. 1A) as a region of relatively weak but significant signal in the cranial neural crest region. Another indication of the fuzzy nature of NC comes from lineage mapping experiments in the chick embryo, which show that cells fated to differentiate as NC, neural plate, epidermis and placodal derivatives are all intermingled in the neural-epidermal boundary region.<sup>2</sup> Nor is there always a clear gap visible between neural plate and epidermal gene expression domains, for example in a double *in situ* with epidermal keratin and the pan-neural marker *NCAM* the two domains are contiguous (Fig. 1B). Expression of keratin genes is also evident in animal caps that have been dissected from embryos injected with BMP antagonists, such as *chordin*, along with a canonical Wnt signal molecule, such as *Wnt3a*. This strongly induces NC gene expression, but at the same time induces keratin gene expression, again to a level lower than that of epidermis, but much higher than the background seen in animal caps from embryos injected with BMP antagonist alone (Fig. 1C). The point of this discussion is that the premigratory NC is a somewhat ambiguously defined cell type, comprising overlapping and intermixed domains of gene expression, morphology and developmental fate. This should be kept in mind when thinking about the genes that control the NC program, i.e., regulatory mechanism giving rise to complex, overlapping and transient cellular identities will likely reflect this complexity. Indeed, many regulatory factors have been associated with NC,<sup>1</sup> a list that continues to grow. Even organizing the undoubtedly incomplete roster into a regulatory flow diagram results in a complex picture.<sup>3</sup> This review will focus primarily on two sets of transcription factors implicated in the earliest stages of NC induction, the *Msx/Dlx* and *TFAP2* families.

---

\*Thomas D. Sargent—Laboratory of Molecular Genetics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, U.S.A.  
Email: sargentt@mail.nih.gov



Figure 1. Overlap of epidermis and neural crest. A) Whole mount in situ hybridization to stage 14 (open neural plate) *Xenopus* embryo with an epidermal keratin probe (XK81). The arrows indicate the cranial NC region, where XK81 hybridization signal is clearly visible, although at a lower level than in the epidermis. B) Double in situ hybridization of similar staged embryo to neural plate (NCAM; purple color) and epidermal (XK81; brownish color) probes. The arrow indicates the cranial NC region, where no gap can be discerned between the epidermal and neural plate domains. Dorsal views, anterior towards top of figure. Panel B reproduced with permission from reference 61 and The Company of Biologists, Ltd. C) Northern blot analysis of an animal cap induction experiment. Embryos were injected with 250 pg of RNA encoding chordin (Chd) or a mixture of 250 pg each chordin and Wnt3a RNA (Chd+Wnt). Animal caps cultured to stage 14 show neuralization by Chd (Sox2 probe) and complete repression of epidermis (XK81 probe). NC is strongly activated by the chordin + Wnt3a treatment (Slug probe), which represses neural plate but also significantly reactivates the epidermal marker. EF1alpha and 18S RNA signals are shown as loading controls.

### Dlx and Msx Genes

Dlx factors are homeodomain proteins, related to the *Drosophila* Distal-less (Dll) gene.<sup>4</sup> They behave as transcriptional activators, at least in coexpression assays.<sup>5,6</sup> In mouse and

human there are six *Dlx* genes, present in three pairs of convergently transcribed genes, each linked to a separate *Hox* cluster.<sup>7</sup> Only four *Dlx* genes have been described to date in *Xenopus*, of these three are known to be transcribed at the mid/late gastrula stage when NC is induced, these are *Dlx3*, *Dlx5* and *Dlx6*.<sup>8,9</sup> Two other *Dlx* genes, *Dlx1* and *Dlx2*, are also expressed in *Xenopus* NC, but later in development.<sup>10</sup> There are eight *Dlx* genes in zebrafish, with *Dlx3b* and *Dlx4b* representing the fish orthologs of the linked pair, *Dlx3* and *Dlx4*, respectively.<sup>11</sup> There is no evidence for the existence of a *Dlx4* ortholog in *Xenopus* either in EST databases or in the *Xenopus tropicalis* genome, which has been largely sequenced (<http://genome.jgi-psf.org/Xentr3/Xentr3.home.html>), so perhaps *Dlx4* is absent in amphibian genomes. In mouse there are three *Msx* genes. These are also homeodomain factors, related to the *Drosophila* muscle segment homeodomain (*msh*) gene.<sup>5</sup> The *Dlx* and *Msx* homeodomains are quite similar, and bind to essentially identical DNA sequences *in vitro*.<sup>6</sup> *Msx* factors behave as transcriptional repressors. *Msx1* can repress target gene transcription by binding to the TATA binding factor TBP,<sup>12</sup> and also by interacting with a linker histone H1b.<sup>13</sup> Importantly, *Dlx* and *Msx* factors can form heterodimers, and this interaction can antagonize the mutual effects on target gene activity.<sup>14,15</sup> In *Xenopus*, *Msx1* and *Msx2* are expressed beginning at or shortly following the midblastula transition, as are the *Dlx* genes. Both gene families are expressed in ventral and lateral tissues, *Msx* in mesoderm and ectoderm, and *Dlx* in ectoderm only.<sup>5,9</sup> This expression is regulated by BMP signaling. *Msx1* is a direct target of such signaling, via a regulatory element in the 5' flanking DNA that associates with Smads factors.<sup>16,17</sup> *Msx2* is likewise controlled by BMP signaling, and in the case of the mouse gene, the regulator element includes binding sites for both a Smads factor and an additional unknown protein that probably confers additional target specificity.<sup>18</sup> In contrast to *Msx*, the *Dlx* factors are not direct targets of the BMP pathway, requiring protein synthesis following BMP exposure.<sup>6</sup> In the ventral ectoderm, there is a graded dependence of *Msx1*, *Dlx3* and *Dlx5/6* on BMP signaling, which can be visualized by treating with increasing dosages of a BMP antagonist such as chordin. The lateral boundaries of *Dlx3* and *Dlx5/6* also differ, and this is consistent with the notion that a BMP signaling is locally weaker near the neural plate boundary compared to more laterally.<sup>8</sup>

There are several lines of evidence suggesting that *Dlx* and *Msx* play important roles in patterning the neural-epidermal border, including the NC. Before discussing these experiments, it is worth reviewing the tools that have been used in them. Gain of function has been accomplished by injecting synthetic mRNA into early cleaving embryos, which results in ectopic protein synthesis. For loss of function, two methods have been successfully employed; antisense and dominant negative overexpression. Most antisense work has been carried out with oligonucleotides based on morpholino backbone chemistry, which yields stable molecules that can base pair with target RNAs and either inhibit translation initiation or intron splicing. Dominant negative interference has been based on the concept that as transcriptional activators, *Dlx* factors can be antagonized by overexpressing derivatives in which the DNA binding domain has been fused to a transcriptional repressor, such as the repression domain from the *Drosophila* engrailed protein.<sup>19</sup> These experimental approaches can be quite informative, but they also have disadvantages and concomitant interpretational caveats. In the case of factor overexpression, the most obvious potential problem is that the level of the expressed protein is usually not known, and could be considerably higher than endogenous protein concentrations. This might lead to spurious interactions with genes or other factors, leading to regulatory artifacts. This is especially relevant to *Dlx* and *Msx* genes due to the similar DNA binding properties and opposite effects on target gene transcription. An illustrative example of this problem can be seen in the conclusion that *Dlx5* functions in setting up the dorsoventral axis in *Xenopus*,<sup>20</sup> based on ectopic overexpression. Since *Dlx5* is not expressed in mesoderm,<sup>9</sup> which is where the axial specification takes place, the ventralizing effect on this tissue is presumably an artifact.

*Xenopus Dlx3* is excluded from the presumptive cranial neural crest domain, and when *Dlx3* mRNA is delivered to this area by microinjection, repression of *slug* and other NC



Figure 2. Repression of NC by truncated Dlx3. Stage 14 *Xenopus* embryo injected into one dorsal ectodermal cell at the eight-cell stage with 100 pg RNA encoding *Xenopus* Dlx3 that has been modified to delete amino acids 1-43 at the N-terminus and 200-277 at the C-terminus, leaving the homeodomain and about 60 residues N-terminal to it, and removing most of the transcriptional activation function of the Dlx3 protein.<sup>6</sup> LacZ RNA was also injected as a linear tracer (blue color). Hybridization with NC marker *Slug* shows complete inhibition on the injected side (arrow). Dorsal view, anterior towards top of figure. D. Khadka and T. Sargent, unpublished data.

markers is observed.<sup>9</sup> Dlx3 overexpression also inhibits expression of neural plate marker genes.<sup>21</sup> Dlx3 overexpression also antagonizes Wnt-beta catenin signaling, and this could be the basis for the negative effect on NC.<sup>9,22</sup> Similar results have been obtained using a zebrafish Dlx3 homeodomain fused to a VP16 activation domain, suggesting that this effect depends on target gene activation.<sup>23</sup> However, the inhibitory effect on NC is also observed with a truncated Dlx3 lacking the entire C-terminal and most of the N-terminal domains, a deletion construct that retains very little capacity to upregulate an artificial target gene<sup>6</sup> (Fig. 2). This makes it less likely that Dlx3 inhibits NC induction via a conventional transcriptional activation mechanism. Could Dlx3 be acting as an antagonist for *Msx1* by competing for DNA binding, or interfering with *Msx* factors by protein-protein interactions? This model would predict a similar inhibitory effect for Dlx5, which is not what has been observed.<sup>9</sup> Furthermore, morpholino knockdown of Dlx3 alone does not seem to have much effect on the neural crest boundary, although there is a transient loss of some otic placode gene expression in *Xenopus*.<sup>24</sup> A similar effect on otic placode has also been observed in the zebrafish using morpholinos targeting Dlx3 and the linked Dlx7 genes,<sup>25</sup> with no obvious effect on neural crest boundaries. These results suggest that Dlx3 plays a role in ear development, but if this factor also functions in controlling the lateral limit of NC, there must be an alternate or alternates that are fully redundant. Dlx5 is not a good candidate in *Xenopus*, as its expression domain differs from that of Dlx3 in the NC. Another variation on the redundancy theme is a model in which absence of Dlx3 from the NC domain is a permissive requirement for NC induction, while the limits of the induced NC domain could be determined by instructive signals.

Dlx5 is expressed more medially and overlaps with NC in the frog embryo, although this might be a bit misleading as the Dlx5-positive cells in the NC region are mostly limited to the

outer cell layer, whereas NC regulators such as *Slug* are mainly expressed in the inner, sensorial layer (Fig. 3). Overexpression of *Dlx5* in *Xenopus* has not been tested extensively, although it has been shown to have little negative effect on NC induction compared to *Dlx3* in animal cap assays.<sup>9</sup> In the chick embryo, ectopic *Dlx5* expression, achieved by electroporation, alters the neural/nonneural boundary.<sup>26</sup> Artinger and colleagues used a dominant negative strategy to test *Dlx* function in frog embryos; the homeodomains from either zebrafish *Dlx3* or *Xenopus* *Dlx5* were fused to the engrailed repressor, intended to antagonize the normal activation function of *Dlx* factors. These constructs also included the ligand binding domain of glucocorticoid receptor to confer inducibility by dexamethasone.<sup>27</sup> This is important because mis-expression of *Dlx* factors in mesoderm results in severe axis disruption, as noted above. As already discussed, such a strategy also is essentially a combined loss of any and all *Dlx* function in the target embryos and tissues. In these experiments, both *Engrailed* fusions yielded loss of both neural plate and neural crest markers, or lateral shift of both.<sup>23</sup> This question has also been recently addressed in zebrafish by this group. In these experiments, loss of function was accomplished by the use of morpholinos designed to block translation or splicing of *Dlx3a* and *Dlx4b*, which are a linked pair in zebrafish and mammalian genomes. Other *Dlx* genes are not expressed at the relevant stages in the fish embryo.<sup>28</sup> Since these two genes have been shown to have largely redundant function in ear development,<sup>25</sup> they were treated in tandem in this study. Loss of *Dlx3a* and *Dlx4b* resulted in elimination of Rohon-Beard cells and trigeminal ganglia, and a rather slight effect on the neural crest, significant but considerably less extensive than what was observed using the dominant negative approach in *Xenopus*. Similar results were obtained with an *Engrailed* fusion in the zebrafish embryo, however, so this difference may reflect species individuality rather than pointing to a problem with the dominant negative approach per se. It would be interesting to see the effects of gene-specific knock-downs for *Dlx* genes in *Xenopus*, but this might require targeting three factors, *Dlx3*, *Dlx5* and *Dlx6*, which might exceed the limits of morpholino oligonucleotides that the frog embryo can tolerate. However in the absence of such data, the interpretation of dominant negative overexpression in *Xenopus* should be considered somewhat tentative. In conclusion, *Dlx* genes are likely to be involved in the early specification of placodes, particularly the otic vesicle, but probably play a relatively minor role in NC induction, and are more important in fine-tuning the response to signals that determine the spatial limits of NC. Other regulators operate at a more upstream level in the initial formation of NC.

Two such factors may be the *Msx1* and *Msx2* homeoproteins. At the end of gastrulation, *Msx1* and *Msx2* RNAs, both of which are transcribed in epidermis, begin to accumulate at higher levels in the neural/epidermal border region. This pattern differs from that of most NC genes in that it is as strong or even stronger in the trunk region as in the cranial domain<sup>29</sup> (Fig. 4). This spatial difference suggests that the NC expression of *Msx* genes is controlled by somewhat different signaling compared to genes like *Slug* that are expressed more broadly in the anterior NC but in a narrow band in the trunk region. One possible difference is that *Msx* genes are more dependent upon canonical Wnt signaling, which would be expected to be locally stronger in the posterior, distant from Wnt antagonists elaborated by anterior tissues.<sup>30</sup> Using a microarray screening procedure, Willert et al<sup>31</sup> determined that in human embryonic carcinoma cells *Msx1* and *Msx2* were direct targets of this signaling pathway, and it is conceivable that this is also the case in the *Xenopus* embryonic NC. At any rate, the abundance (or conspicuous absence) of any regulatory factor in an embryonic domain is good preliminary evidence for a developmental role. This has been tested using the dominant negative approach by Mayor and colleagues.<sup>29</sup> These experiments were carried out in a similar manner to the *Dlx* experiments just described, except that to generate the negative interfering form of *Msx1* the N-terminal third of the protein was deleted. Fusions to activation or repressor domains were not employed. As with the previous work, fusion to the glucocorticoid receptor ligand binding domain was used to enable dexamethasone induction, to avoid the axis disruption resulting from *Msx1* overexpression during gastrulation. Overexpression of




Figure 3. Deep versus superficial expression of Dlx5 and Slug genes. Panels A and B show whole mount in situ hybridizations of neurula stage *Xenopus* embryos to Slug and Dlx5 probes, respectively. Dorsal views, anterior to right. Transverse sections (dorsal side up) show that Slug is primarily transcribed in the deep ectodermal cells (C; arrows), whereas Dlx5 expression is restricted to the superficial cells in the NC domain (D; arrows). T. Luo and T. Sargent, unpublished data.




Figure 4. Comparison of Msx1 and Slug expression. Neurula stage *Xenopus* embryos hybridized in situ to Msx1 (A) and Slug (B) probes, showing that the Msx1 expression is much broader in the posterior region (bottom). D. Khadka and T. Sargent, unpublished data.

*Msx1* in one side of *Xenopus* embryos after gastrulation resulted in an expansion of NC, visualized with *FoxD3*, *slug* and *snail* markers. This was accompanied by reduction in both epidermal (keratin *XK81*) and neural plate (*Sox2*) domains, although this effect is somewhat more difficult to appreciate due to the relatively large size of these domains compared to NC. The negative *Msx1* had the opposite effect, reducing NC and expanding neural plate and epidermis. Interestingly, this loss of function phenotype could be significantly rescued by either *slug* or *snail* overexpression, while *Msx1* was not able to rescue the effects of dominant negative forms of either factor. This suggests that *Msx1* functions upstream from both *slug* and *snail*, possible acting as one of the first transcriptional effectors of NC induction. In subsequent work by Mayor and colleagues suggests that the transcriptional relationship between *Slug* and *Msx* ends by stage 15, after which time these two factors may act in an antagonistic manner to regulate apoptosis in NC cells.<sup>32</sup>

Thus we are left with the intriguing possibility that NC specification at the level of transcription is initiated by a repressor molecule. This of course raises the question of what is repressed, and how this in turn leads to the up-regulation of *Snail* and *slug*, which are also repressors. Another issue is that the use of dominant negative overexpression, as with the *Dlx* work, is open to the criticism regarding inappropriate targets and possible interference with other regulatory proteins. At this writing, we are completing a series of experiments on *Msx1* and *Msx2* loss of function using splice-inhibitory morpholino antisense oligonucleotides. These data confirm the importance of *Msx* genes in NC induction, although some aspects of NC seem to be independent of *Msx* function, as is epidermal development and dorsoventral axis specification (Khadka and Sargent, unpublished).

## TFAP2

The transcription factor AP2 (TFAP2) is a family encoded by a total of five genes scattered at diverse sites in mouse and human genomes, designated alpha through epsilon, or TFAP2a, b, c, d and e. TFAP2 proteins have a basic helix-span-helix DNA binding and protein dimerization domain near the carboxy terminus. All five bind similar DNA elements with a consensus sequence of GCCNNNGGC<sup>33</sup> TFAP2 factors function as transcriptional activators via a proline/aromatic-rich activation domain located near the amino terminus. TFAP2 function also requires dimerization, and dominant interfering variants of TFAP2 have been generated by deletion of the activation domain, and also occur naturally, such as the variants associated with Char syndrome.<sup>34</sup> Members of the TFAP2 family have been implicated in many biological processes, including development and disease.<sup>35</sup> A number of directly regulated TFAP2 target genes have been identified, ranging in function from structural proteins such as keratin<sup>36</sup> to regulatory factors such as Hox genes.<sup>37,38</sup>

TFAP2a, the archetypical member of this family, has long been recognized as a characteristic factor expressed in neural crest.<sup>39</sup> Gene targeting in the mouse for TFAP2a was initially reported in 1996.<sup>40,41</sup> The null phenotype is a highly dysmorphic perinatal lethal. Among the most severely disrupted tissues were the facial bones, particularly the mandible, maxilla and frontonasal prominence. In addition, cranial ganglia and the heart outflow tract were abnormal. All of these derive largely from NC, supporting a role for TFAP2a in this lineage. TFAP2b and TFAP2c are also expressed in NC<sup>35</sup> but disruption of these genes does not have an apparent effect on NC induction or development in the mouse.<sup>42,43</sup>

An important aspect of the TFAP2a null phenotype is that the induction of NC and at least the early migratory processes do not seem to be affected much. Expression of *Pax3* and *Twist*, two early NC markers, is essentially normal, and multiple aspects of NC migration can be observed.<sup>41,44</sup> Consequently, TFAP2a function in mouse appears to be more important in the terminal stages of NC cell differentiation.<sup>40,41,44</sup> Since TFAP2a is strongly expressed in NC, it might be expected that the loss of this factor would result in a largely cell-autonomous phenotype. However, this does not seem to be the entirely the case in the mouse, based on the results of a conditional TFAP2a knock out phenotype.<sup>45</sup> These embryos were generated by crossing a



line containing an TFAP2a allele including lox recognition sites with mice expressing Cre recombinase driven by a Wnt1 promoter,<sup>46</sup> resulting in ablation of TFAP2a expression in NC lineages (floxed). Floxed mice exhibited deficiencies in NC derivatives, reminiscent of the TFAP2a null phenotype, but with lower penetrance and with generally less severe craniofacial defects. For example, palatal shelves formed and elevated, but did not fuse, whereas in TFAP2a null pups these structures are absent.<sup>40,41</sup> Also, cranial ganglia were not affected by NC-specific TFAP2a loss, in contrast to severe reduction in the TFAP2a null phenotype. The less drastic phenotypic of floxed TFAP2a pups enabled further analysis of NC derivatives. For example, surviving floxed pups exhibited defects in melanocytes that could not be evaluated in the original TFAP2a nulls due to the early lethality.<sup>45</sup> Similarly, the stapes bone, absent in the TFAP2a null, was particularly reduced compared to other middle ear ossicles. This is interesting in light of the TFAP2a null phenotype in zebrafish, discussed below. The most important lesson from these experiments is perhaps that TFAP2a functions in NC not only in a cell autonomous fashion, accounting for the similarities between the original null and the NC floxed null phenotypes, but also in a noncell autonomous manner, accounting for the differences. Thus TFAP2a must regulate the expression of genes in NC-adjacent tissues encoding signaling factors that influence the terminal differentiation of NC cells. The identification of these TFAP2a-dependent genes and signals will be an exciting area of research in the coming years.

In zebrafish embryos, TFAP2a is first expressed in nonneural ectoderm, then is strongly upregulated in the NC. Interestingly the NC expression domain overlaps only partially with broadly expressed NC markers like *Foxd3* and *Sna2*, which contrasts with the pattern in *Xenopus* (see below) and could account for some of the interspecies differences in loss of function phenotypes. TFAP2a is also expressed in intermediate and lateral plate mesoderm, which is not the case in *Xenopus*. Mutagenesis screens for zebrafish embryonic craniofacial anomalies led to the identification of two allelic recessive lethal mutations, *montblanc (mob)*<sup>47</sup> and *lockjaw (low)*,<sup>48</sup> both of which are due to loss of function point mutations in the zebrafish TFAP2a gene.<sup>49,50</sup> The TFAP2a null phenotype in zebrafish is similar to the floxed TFAP2a mouse. The zebrafish TFAP2a null craniofacial skeleton is dysmorphic, but this is less devastating than in the TFAP2a null mouse and is mainly restricted to hypoplasia of derivatives of pharyngeal arches 2 (hyoid) through the branchial (gill) arches. Particularly affected is the hyosymplectic cartilage, which develops into a supporting bone in teleosts, but is the precursor to the stapes ossicle in mammals, and also greatly reduced in the floxed mouse. Also, like the floxed TFAP2 mouse, the zebrafish mutants exhibit reductions in pigment cells. This supports a phylogenetically conserved function for this factor in NC development, but implies some differences in the level of functional redundancy or the status of TFAP2a within the regulatory framework.

Both *low* and *mob* embryos have been analyzed using in situ hybridization with several molecular markers of NC, and the results are in basic agreement. Some early markers such as *foxd3* and *sna2* are not much affected, while others such as *crestin* and *Sox9* show fairly conspicuous reductions in certain subdomains. At later stages migratory markers such as *Dlx2* and *Epha4* are reduced in the affected hyoid and more posterior arch NC.<sup>38,49,50</sup> This suggests that TFAP2 plays a less essential role during the early phases of NC development compared to later differentiation stages, and differs in function in different subsets of the NC. In the absence of TFAP2, affected NC cells undergo apoptosis and the target structures are absent or hypoplastic, similar to the mouse knockout data.

The question of cell autonomy for TFAP2 has been addressed in zebrafish by cell transplantation.<sup>50</sup> Wild type NC cells transplanted into the region of NC that gives rise to second pharyngeal arch migrated and differentiated normally, and yielded some rescue of tissue missing in mutants. Mutant cells transplanted into wt recipients for the most part did not migrate normally into the branchial arches or contribute to cartilage. These results are consistent with the conclusion that TFAP2 functions in a subset of NC, but in a cell-autonomous manner. This is somewhat in contrast to the mouse, but an exact comparison is difficult due to the differences in experimental approaches.



In *Xenopus* the TFAP2 family is not as well characterized. All of the existing data have been obtained with the ortholog of TFAP2a. Other TFAP2 family members exist, however, represented as ESTs in *Xenopus laevis* and *X. tropicalis* databases. As of this writing our laboratory has characterized TFAP2b and TFAP2c, both of which are expressed at approximately the same time and place as TFAP2a (Y. Zhang, T. Sargent, unpublished). TFAP2a is first expressed throughout the ectoderm in *Xenopus*, then becomes cleared from the prospective neural plate during gastrulation. By the end of gastrulation TFAP2a is up-regulated in NC, but still remains expressed at a significant level in the epidermis, which continues throughout development.<sup>36</sup> Loss of function experiments have been done using both antisense and dominant negative approaches. Morpholino antisense oligonucleotides injected into one blastomere at the two-cell stage resulted in substantial, inhibition of Slug and Sox9 expression<sup>51</sup> but had little if any effect on Pax3, another early NC marker. Similar results have been obtained with a dominant negative TFAP2a lacking the activation domain. These results suggest that TFAP2a may be essential for early induction events in *Xenopus*, contrasting with zebrafish and mouse, where loss of TFAP2a leaves induction and migration largely unaffected. Another apparent difference between *Xenopus* and the other two species is the effect of global loss of TFAP2a, accomplished by radial injection of antisense oligonucleotide. These experiments were done using diethylethylene diamine (DEED) antisense oligonucleotides, which unlike the morpholino antisense strategy results in RNaseH-dependent cleavage of target RNAs.<sup>52,53</sup> Such embryos failed to gastrulate. The ectoderm was unable to engulf the mesoderm and collapsed into a convoluted mass on the animal hemisphere. This phenotype could be largely rescued by coinjection of a TFAP2a derivative with silent mutations rendering it resistant to the DEED oligonucleotide. A similar phenotype was also obtained using dominant negative TFAP2a. The gastrulation failure was accompanied by strong inhibition of epidermal marker genes (keratin). The dominant-negative TFAP2a, in which the activation domain had been replaced with a repressor domain from the *Drosophila* engrailed protein, also resulted in activation of neural genes concomitant with repression of epidermis. This was not observed with the DEED oligonucleotide, presumably indicating incomplete destruction of TFAP2a RNA. Thus in *Xenopus* it appears that TFAP2a is required for induction of NC, and also required earlier for epidermal function and gastrulation. One possibility is that the early loss of some NC markers in TFAP2a-inhibited embryos is a consequence of blocking the production of one or more inductive signals from epidermis that are needed for NC induction. This could be tested by targeting either a dominant negative TFAP2 or antisense specifically to the NC, avoiding expression in adjacent epidermis. This is impractical in *Xenopus*—even at the 32-cell stage, single blastomeres will give rise to both of these tissue types. In any case it is clear enough from the experiments outlined above that in the mouse there are TFAP2-dependent signals necessary for NC development that emanate from outside the NC, while this is apparently not the case in zebrafish based on the cell transplantation data. Thus it seems likely that TFAP2a, and perhaps other TFAP2's may function somewhat differently in various vertebrates.

In *Xenopus* it is relatively easy to carry out gain of function experiments by injecting synthetic mRNA into fertilized eggs, or into blastomeres fated to become particular tissues. TFAP2a RNA injected into one dorsal ectodermal blastomere at the 8 or 16 cell stage resulted in the expansion of Slug and Sox9 expression into the neural plate, accompanied by downregulation of neural markers indicated a neural to NC transiting had taken place as the result of ectopic TFAP2a activity.<sup>51</sup> This was also accomplished in animal cap explants. In these experiments, NC induction was achieved first by injecting synthetic mRNA for Wnt3a and for chordin.<sup>54,55</sup> When the chordin concentration was increased to very high levels, sufficient to extinguish BMP signaling entirely, as indicated by the loss of Dlx5 expression, the explanted ectoderm reverted to a posterior neural identity, as indicated by loss of all NC markers and activation of Sox2 expression. If the same treatment was performed with TFAP2a RNA added to the cocktail, the response was largely reversed. Most NC marker




Figure 5. Dependence of NC induction on BMP signal strength and AP2 in *Xenopus* animal cap experiments. A) Increasing doses of RNA encoding chordin (Chd) from 10 pg to 3 ng, injected along with RNA encoding Wnt-3a induces NC gene expression (TFAP2a, Sox9, Slug, Xtwi) and represses Dlx genes and neural gene expression (Sox2, Otx2), except at the highest dose of Chd, which results in induction of the pan-neural Sox2, but not the anterior neural Otx2 genes, and silences the NC genes. B) Addition of TFAP2a reverses the NC to neural plate transition shown in (A). Modified from Luo et al, 2003.<sup>51</sup>

genes became active, neural genes were silenced (Fig. 5). This supports a model in which TFAP2a mediates the attenuated BMP signal which, in conjunction with a canonical Wnt signal (or FGF,<sup>56</sup> induces NC).

**NC Regulatory Pathways Problems and Prospects**

Does TFAP2 fit into a hierarchy of NC regulators? A good place to start is the epistatic pathway proposed for *Xenopus* by Mayor and colleagues in which Msx1 is upstream from Snail, followed by Slug.<sup>29</sup> In animal caps primed with Wnt/beta catenin signaling, and in embryonic neurectoderm, TFAP2a can induce Slug. There are no data regarding Msx1 or Snail, so for the sake of discussion we can place TFAP2a between Snail and Slug. TFAP2a is not a direct target of BMP signaling since it is not induced by BMP in the presence of cycloheximide,<sup>36</sup> and therefore there is presumably at least one activator factor upstream from TFAP2a that is synthesized in response to BMP. Both Msx1 and Snail are repressors, so this hypothetical TFAP2a activator (HTA) must be inserted in the pathway, i.e., downstream from Snail. Furthermore, as a repressor, the simplest way for Snail to activate HTA would be to repress a repressor of HTA (RHITA). Likewise, for Msx to positively regulate Snail, a repressor of Snail (RS) could be inhibited by Msx. This gives the following linear

pathway: Msx1 -| RS -|Snail -| RHTA -|HTA -> TFAP2 -> Slug. Additional steps downstream from Slug would presumably entail another repressed repressor event. Nor is it clear that another step is not required for TFAP2 to activate Slug. This pathway is complicated further by the apparent direct regulation of Slug by Wnt beta catenin signaling,<sup>57</sup> and the possibility that Msx is also a beta catenin target (see above). This is a complex event chain, all of which must take place within a fairly brief time interval, between late gastrula and early neurula. Indeed, it is difficult to discern any temporal differences in the expression of any of these known genes in the NC domain. Some steps, such as repression, could occur by protein interactions that might be essentially instantaneous, but it would seem that the linear model is probably too slow, cumbersome and too simple to account for all the available information.

Another argument against linear control of NC is the differences that exist between species. For example, Slug and Snail differ in expression pattern and presumably in function in various vertebrates.<sup>58</sup> Likewise, Msx1 and Msx2 null phenotypes in mouse are quite different,<sup>59,60</sup> and neither results in massive loss of NC. This could reflect redundancy, but could just as easily be due to differences in function in mouse compared to frog. There are other examples, and as data become available for orthologous genes in multiple species, this number will probably increase. A strict linear pathway would be inherently less tolerant of evolutionary change, compared to a network with plenty of redundancy and positive and negative feedback. Altering the status of one or a few regulatory factors in such a network could lead to alterations in the end product, as opposed to its elimination. This might help explain the tremendous variation in facial morphology among the vertebrates, a factor that has contributed very significantly to the adaptive success of this phylum.

## References

- Huang X, Saint-Jeannet JP. Induction of the neural crest and the opportunities of life on the edge. *Developmental Biology* 2004; 275(1):1-11.
- Streit A. Extensive cell movements accompany formation of the otic placode. *Dev Biol* 2002; 249(2):237-254.
- Meulemans D, Bronner-Fraser M. Gene-regulatory interactions in neural crest evolution and development. *Developmental Cell* 2004; 7(3):291-299.
- Cohen SM, Bronner G, Kuttner F et al. Distal-less encodes a homeodomain protein required for limb development in *Drosophila*. *Nature* 1989; 338(6214):432-434.
- Bendall AJ, Abate-Shen C. Roles for Msx and Dlx homeoproteins in vertebrate development. *Gene* 2000; 247(1-2):17-31.
- Feledy JA, Morasso MI, Jang SI et al. Transcriptional activation by the homeodomain protein distal-less 3. *Nucleic Acids Res* 1999; 27(3):764-770.
- Stock DW, Ellies DL, Zhao Z et al. The evolution of the vertebrate Dlx gene family. *Proc Natl Acad Sci USA* 1996; 93(20):10858-10863.
- Luo T, Matsuo-Takasaki M, Lim JH et al. Differential regulation of Dlx gene expression by a BMP morphogenetic gradient. *Int J Dev Biol* 2001; 45(4):681-684.
- Luo T, Matsuo-Takasaki M, Sargent TD. Distinct roles for Distal-less genes Dlx3 and Dlx5 in regulating ectodermal development in *Xenopus*. *Mol Reprod Dev* 2001; 60(3):331-337.
- Papalopulu N, Kintner C. *Xenopus* Distal-less related homeobox genes are expressed in the developing forebrain and are induced by planar signals. *Development* 1993; 117(3):961-975.
- Panganiban G, Rubenstein JL. Developmental functions of the Distal-less/Dlx homeobox genes. *Development* 2002; 129(19):4371-4386.
- Zhang H, Catron KM, Abate-Shen C. A role for the Msx-1 homeodomain in transcriptional regulation: Residues in the N-terminal arm mediate TATA binding protein interaction and transcriptional repression. *Proc Natl Acad Sci USA* 1996; 93(5):1764-1769.
- Lee H, Habas R, Abate-Shen C. MSX1 cooperates with histone H1b for inhibition of transcription and myogenesis. *Science* 2004; 304(5677):1675-1678.
- Zhang H, Hu G, Wang H et al. Heterodimerization of Msx and Dlx homeoproteins results in functional antagonism. *Mol Cell Biol* 1997; 17(5):2920-2932.
- Bryan JT, Morasso MI. The Dlx3 protein harbors basic residues required for nuclear localization, transcriptional activity and binding to Msx1. *J Cell Sci* 2000; 113(Pt 22):4013-4023.

16. Alvarez Martinez CE, Binato R, Gonzalez S et al. Characterization of a Smad motif similar to *Drosophila* mad in the mouse *Msx 1* promoter. *Biochem Biophys Res Commun* 2002; 291(3):655-662.
17. Suzuki A, Ueno N, Hemmati-Brivanlou A. *Xenopus msx1* mediates epidermal induction and neural inhibition by BMP4. *Development* 1997; 124(16):3037-3044.
18. Brugger SM, Merrill AE, Torres-Vazquez J et al. A phylogenetically conserved cis-regulatory module in the *Msx2* promoter is sufficient for BMP-dependent transcription in murine and *Drosophila* embryos. *Development* 2004; 131(20):5153-5165.
19. Jaynes JB, O'Farrell PH. Active repression of transcription by the engrailed homeodomain protein. *EMBO J* 1991; 10(6):1427-1433.
20. Miyama K, Yamada G, Yamamoto TS et al. A BMP-inducible gene, *dlx5*, regulates osteoblast differentiation and mesoderm induction. *Dev Biol* 1999; 208(1):123-133.
21. Feledy JA, Beanan MJ, Sandoval JJ et al. Inhibitory patterning of the anterior neural plate in *Xenopus* by homeodomain factors *Dlx3* and *Msx1*. *Dev Biol* 1999; 212(2):455-464.
22. Beanan MJ, Feledy JA, Sargent TD. Regulation of early expression of *Dlx3*, a *Xenopus* anti-neural factor, by beta-catenin signaling. *Mech Dev* 2000; 91(1-2):227-235.
23. Woda JM, Pastagia J, Mercola M et al. *Dlx* proteins position the neural plate border and determine adjacent cell fates. *Development* 2003; 130(2):331-342.
24. Saint-Germain N, Lee YH, Zhang YH et al. Specification of the otic placode depends on *Sox9* function in *Xenopus*. *Development* 2004; 131(8):1755-1763.
25. Solomon KS, Fritz A. Concerted action of two *dlx* paralogs in sensory placode formation. *Development* 2002; 129(13):3127-3136.
26. McLaren KW, Litsiou A, Streit A. *DLX5* positions the neural crest and preplacode region at the border of the neural plate. *Dev Biol* 2003; 259(1):34-47.
27. Kolm PJ, Sive HL. Efficient hormone-inducible protein function in *Xenopus laevis*. *Dev Biol* 1995; 171(1):267-272.
28. Kaji T, Artinger KB. *dlx3b* and *dlx4b* function in the development of Rohon-Beard sensory neurons and trigeminal placode in the zebrafish neurula. *Dev Biol* 2004; 276(2):523-540.
29. Tribulo C, Aybar MJ, Nguyen VH et al. Regulation of *Msx* genes by a *Bmp* gradient is essential for neural crest specification. *Development* 2003; 130(26):6441-6452.
30. Mayor R, Young R, Vargas A. Development of neural crest in *Xenopus*. *Curr Top Dev Biol* 1999; 43:85-113.
31. Willert J, Epping M, Pollack JR et al. A transcriptional response to Wnt protein in human embryonic carcinoma cells. *BMC Dev Biol* 2002; 2(1):8.
32. Tribulo C, Aybar MJ, Sanchez SS et al. A balance between the anti-apoptotic activity of *Slug* and the apoptotic activity of *msx1* is required for the proper development of the neural crest. *Dev Biol* 2004; 275(2):325-342.
33. Mohibullah N, Donner A, Ippolito JA et al. SELEX and missing phosphate contact analyses reveal flexibility within the AP-2[alpha] protein: DNA binding complex. *Nucleic Acids Res* 1999; 27(13):2760-2769.
34. Satoda M, Zhao F, Diaz GA et al. Mutations in *TFAP2B* cause Char syndrome, a familial form of patent ductus arteriosus. *Nat Genet* 2000; 25(1):42-46.
35. Hilger-Eversheim K, Moser M, Schorle H et al. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. *Gene* 2000; 260(1-2):1-12.
36. Luo T, Matsuo-Takasaki M, Thomas ML et al. Transcription factor AP-2 is an essential and direct regulator of epidermal development in *Xenopus*. *Dev Biol* 2002; 245(1):136-144.
37. Maconochie M, Krishnamurthy R, Nonchev S et al. Regulation of *Hoxa2* in cranial neural crest cells involves members of the AP-2 family. *Development* 1999; 126(7):1483-1494.
38. Knight RD, Javidan Y, Nelson S et al. Skeletal and pigment cell defects in the lockjaw mutant reveal multiple roles for zebrafish *tfap2a* in neural crest development. *Dev Dyn* 2004; 229(1):87-98.
39. Mitchell PJ, Timmons PM, Hebert JM et al. Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis. *Genes Dev* 1991; 5(1):105-119.
40. Schorle H, Meier P, Buchert M et al. Transcription factor AP-2 essential for cranial closure and craniofacial development. *Nature* 1996; 381(6579):235-238.
41. Zhang J, Hagopian-Donaldson S, Serbedzija G et al. Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. *Nature* 1996; 381(6579):238-241.
42. Moser M, Pscherer A, Roth C et al. Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. *Genes Dev* 1997; 11(15):1938-1948.
43. Auman HJ, Nottoli T, Lakiza O et al. Transcription factor AP-2gamma is essential in the extra-embryonic lineages for early postimplantation development. *Development* 2002; 129(11):2733-2747.

44. Brewer S, Jiang X, Donaldson S et al. Requirement for AP-2alpha in cardiac outflow tract morphogenesis. *Mech Dev* 2002; 110(1-2):139-149.
45. Brewer S, Feng W, Huang J et al. Wnt1-Cremediated deletion of AP-2alpha causes multiple neural crest-related defects. *Dev Biol* 2004; 267(1):135-152.
46. Danielian PS, Muccino D, Rowitch DH et al. Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase. *Curr Biol* 1998; 8(24):1323-1326.
47. Neuhauss SC, Solnica-Krezel L, Schier AF et al. Mutations affecting craniofacial development in zebrafish. *Development* 1996; 123:357-367.
48. Schilling TF, Piotrowski T, Grandel H et al. Jaw and branchial arch mutants in zebrafish I: Branchial arches. *Development* 1996; 123:329-344.
49. Barrallo-Gimeno A, Holzschuh J, Driever W et al. Neural crest survival and differentiation in zebrafish depends on *mont blanc/tfap2a* gene function. *Development* 2004; 131(7):1463-1477.
50. Knight RD, Nair S, Nelson SS et al. *lockjaw* encodes a zebrafish *tfap2a* required for early neural crest development. *Development* 2003; 130(23):5755-5768.
51. Luo T, Lee YH, Saint-Jeannet JP et al. Induction of neural crest in *Xenopus* by transcription factor AP2alpha. *Proc Natl Acad Sci USA* 2003; 100(2):532-537.
52. Dagle JM, Littig JL, Sutherland LB et al. Targeted elimination of zygotic messages in *Xenopus laevis* embryos by modified oligonucleotides possessing terminal cationic linkages. *Nucleic Acids Res* 2000; 28(10):2153-2157.
53. Dagle JM, Weeks DL. Selective degradation of targeted mRNAs using partially modified oligonucleotides. *Methods Enzymol* 2000; 313:420-436.
54. Saint-Jeannet JP, He X, Varmus HE et al. Regulation of dorsal fate in the neuraxis by Wnt-1 and Wnt-3a. *Proc Natl Acad Sci USA* 1997; 94(25):13713-13718.
55. LaBonne C, Bronner-Fraser M. Neural crest induction in *Xenopus*: Evidence for a two-signal model. *Development* 1998; 125(13):2403-2414.
56. Monsoro-Burq AH, Fletcher RB, Harland RM. Neural crest induction by paraxial mesoderm in *Xenopus* embryos requires FGF signals. *Development* 2003; 130(14):3111-3124.
57. Vallin J, Thuret R, Giacomello E et al. Cloning and characterization of three *Xenopus* slug promoters reveal direct regulation by *Left/beta-catenin* signaling. *J Biol Chem* 2001; 276(32):30350-30358.
58. Locascio A, Manzanares M, Blanco MJ et al. Modularity and reshuffling of *Snail* and *Slug* expression during vertebrate evolution. *Proc Natl Acad Sci USA* 2002; 99(26):16841-16846.
59. Satokata I, Ma L, Ohshima H et al. *Msx2* deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. *Nat Genet* 2000; 24(4):391-395.
60. Satokata I, Maas R. *Msx1* deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. *Nat Genet* 1994; 6(4):348-356.
61. Kishi M, Mizuseki K, Sasai N et al. Requirement of *Sox2*-mediated signaling for differentiation of early *Xenopus* neuroectoderm. *Development* 2000; 127(4):791-800.